BioCentury 20-Year Timeline

Timeline created by deepa in Business

Timeline Text view

Event Date:	Event Title:	Event Description:
01/11/1993	BioCentury launched at H&Q	BioCentury launched at H&Q See BioCentury, Jan. 11, 1993
01/18/1993	Centocor halts Centoxin sepsis trial	See BioCentury Extra, Jan. 18, 1993
02/08/1993	BIO formed
05/01/1993	Human Genome Sciences and SmithKline sign the first big genomics deal
07/23/1993	Chiron's Betaseron first approved beta interferon	See BioCentury, July 26, 1993
11/20/1993	Clinton healthcare reform bill introduced	See BioCentury Extra, Oct. 28, 1993
03/31/1994	Millennium starts string of large genomics deals (Roche)	See BioCentury, April 4, 1994
09/23/1994	David Blech bank fails	See BioCentury, Sept. 26, 1994
11/21/1994	ReoPro approved (Sweden), changing angioplasty treatment	See BioCentury Extra, Dec. 22, 1994
12/06/1995	First HIV protease inhibitor, Roche's Invirase
01/18/1996	MedImmune's RespiGam approved to treat RSV	See BioCentury, Jan. 22, 1996
07/02/1996	Qiagen, first German biotech IPO	See BioCentury, July 15, 1996
07/05/1996	Dolly the sheep cloned
09/15/1997	Fenfluramine drugs withdrawn	See BioCentury, Sept. 22, 1997
11/21/1997	FDA Modernization Act becomes law	See BioCentury, Nov. 10, 1997
03/11/1998	British Biotech meltdown	See BioCentury, March 16, 1998
07/16/1998	Celgene's Thalomid approved for leprosy
09/25/1998	First targeted cancer therapy, Genentech's Herceptin	See BioCentury, Sept. 8, 1998
11/02/1998	FDA approves first TNF alpha inhibitor, Immunex's Enbrel, for RA
12/01/1998	Gates Foundation begins large-scale funding of neglected diseases
02/20/1999	U.K.'s NICE created
06/04/1999	Roche exercises option to acquire remainder of Genentech	See BioCentury, June 7, 1999
07/20/1999	Genentech: 2nd coming
07/21/1999	J&J buys Centocor for $4.9B	See BioCentury, May 10, 1999
09/17/1999	Jesse Gelsinger dies in gene therapy trial	See BioCentury, Dec. 13, 1999
12/16/1999	IPO window explodes	See BioCentury, Dec. 20, 1999
03/14/2000	Genomics bubble bursts on erroneous reports that genes can't be patented	See BioCentury, March 20, 2000
06/26/2000	Human genome sequenced
10/23/2000	Reg FD takes effect	See BioCentury, Oct. 23, 2000
05/10/2001	May 01 - FDA approves Novartis' Gleevec, changing CML from fatal to chronic
08/09/2001	Bush compromise on stem cells	See BioCentury Extra, Aug. 9, 2001
09/11/2001	9/11 and anthrax attacks spur biodefense	See BioCentury, Oct. 8, 2001
12/16/2001	Amgen acquires Immunex for $10.4B	See BioCentury, Dec. 17, 2001
01/18/2002	ImClone scandal	See BioCentury, Jan. 22, 2002
02/22/2002	First biotech financing >$1B, Amgen $2.5B convert
07/30/2002	Sarbanes-Oxley becomes law
09/25/2002	AnGes, first Japanese biotech IPO
02/10/2003	Spitzer Wall Street deal splits bankers and sellside	See BioCentury, Feb. 10, 2003
02/26/2003	SARS first reported in Asia
06/23/2003	Biogen, Idec merge	See BioCentury, June 30, 2003
02/24/2004	Yamanouchi, Fujisawa merge to form Astellas	See BioCentury, March 8, 2004
03/24/2004	Biocon IPO marks emergence of Indian biotech	See BioCentury, April 12, 2004
07/21/2004	Germany forms IQWiG to assess cost-benefit
09/30/2004	Merck pulls Vioxx	See BioCentury, Oct. 4, 2004
11/02/2004	California passes $3B stem cell initiative (Prop. 71)
02/28/2005	Biogen Idec, Elan suspend Tysabri sales	See BioCentury, March 7, 2005
06/30/2005	Europe creates biosimilar pathway	See BioCentury, July 18, 2005
01/20/2006	Sanofi's Ketek prompts FDA to reassess standards for antibiotics for community-acquired infections	See BioCentury, June 26, 2006
04/17/2006	EC approves first biosimilar, Sandoz's Omnitrope
06/05/2006	Tysabri relaunched	See BioCentury, March 13, 2006
06/08/2006	First vaccine to prevent cancer, Merck's Gardasil HPV vaccine
03/09/2007	FDA adds black box to ESA labels	See BioCentury, March 12, 2007
04/23/2007	AstraZeneca buys MedImmune for $15.6B	See BioCentury, April 30, 2007
05/21/2007	Avandia meta-analysis creates fear of CV side effects from diabetes drugs	See BioCentury, May 28, 2007
09/04/2007	NICE agrees to pay for performance deal for Velcade	See BioCentury, June 18, 2007
09/27/2007	FDA Amendments Act of 2007 becomes law	See BioCentury, Sept. 24, 2007
12/17/2008	FDA issues CV guidance for diabetes drugs	See BioCentury, Dec. 15, 2008
03/09/2009	Obama lifts ban on government funding of embryonic stem cell research
03/12/2009	Roche buys Genentech, again
06/11/2009	WHO declares H1N1 a pandemic
03/23/2010	Obama signs Patient Protection and Affordable Care Act	See BioCentury, March 29, 2010
04/29/2010	First cancer immunotherapy, Dendreon's Provenge	See BioCentury, May 3, 2010
04/08/2011	Sanofi acquires Genzyme for $20.1B + CVR
05/13/2011	First HCV protease inhibitors, Merck's Victrelis and Vertex's Incivek	See BioCentury, June 20, 2011
08/17/2011	First simultaneous approval of Rx-Dx combination since Herceptin, Zelboraf and companion Dx from Roche and Daiichi Sankyo for melanoma	See BioCentury, Aug. 22, 2011